Company News »

AtriCure Announces Upcoming Investor Conference Schedule

Business Wire
Share on StockTwits
Published on

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Stifel Healthcare Conference 2014 at the Palace Hotel in New York City on Tuesday, November 18, 2014. Management is scheduled to present at 3:35 p.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation on the Investors page of AtriCure’s corporate website at www.atricure.com.

AtriCure management is scheduled to present at the Canaccord 2014 Medical Technologies & Diagnostics Forum at the Westin Grand Central in New York City on Thursday, November 20, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation on the Investors page of AtriCure’s corporate website at www.atricure.com.

AtriCure management is also scheduled to present at the Piper Jaffray 26th Annual Healthcare Conference at the Palace Hotel in New York City on Wednesday, December 3, 2014. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation on the Investors page of AtriCure’s corporate website at www.atricure.com.

About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s SynergyTM Ablation System is the first and only surgical device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage Management (LAAM) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 33.5 million people worldwide.

Share on StockTwits